The Wellcome Trust An alternative source for funding Dr Ann - - PowerPoint PPT Presentation

The Wellcome Trust An alternative source for funding

Dr Ann Mills-Duggan Sydney March 2013

About us

Global charitable foundation dedicated to achieving extraordinary improvements in health by supporting the brightest minds.

Our history

• Independent charity with strong international

presence

• Support over 3000 researchers in more

than 40 countries

• Endowment at the time of Sir Henry

Wellcome’s death in 1936 - £73,048

• Now ~£14 billion
• Spend ~£640 million per year
• Translational Funding > £80 million

The translation gap

Technology Transfer: Our Purpose

Bridge the gap between fundamental research and commercial application. Fund applied research and development projects to a stage where they are attractive to a follow-

• n funder, such as

venture capital firms, industry and public- private partnerships.

Translational funding to date

Input 235 projects supported Range: £25K - £11.2M £385 million committed Output £806.3 million leveraged 23 exits via M&A/listing or licensing 9 products launched

Diagnostics 10% Enabling Technology 22% Medical Devices 31% Regenerative Medicine 7% Therapeutics 24% Vaccines 6%

Technology types funded

Cardiovascular & Circulatory 13% Gastrointestinal 2% Infectious Diseases 18% Metabolic & Endocrinology 5% Musculo-skeletal 8% Neurology 11% Oncology 11% Ophthalmology 5% Respiratory 4% Veterinary 3% Other 20%

Therapeutic areas funded

Funding schemes

Translation Fund R&D for Affordable Healthcare in India Innovative Engineering for Health (with EPSRC) Health Innovation Challenge Fund

(with UK Department

• f Health)

Seeding Drug Discovery Pathfinders

Funding schemes – global eligibility

Translation Fund R&D for Affordable Healthcare in India Innovative Engineering for Health (with EPSRC) Health Innovation Challenge Fund

(with UK Department

• f Health)

Seeding Drug Discovery Pathfinders

• Pilot funding for Academic-Industry partnerships to

develop early-stage applied research and development projects in orphan and neglected disease areas

• Any aspect of product development can be considered
• Wellcome Trust contribution capped at £100 000 -

evidence of matching funding contribution from company partner expected

Pathfinders

Funding schemes

Translation Fund Seeding Drug Discovery

Dispelling Some Myths

• Previous Wellcome Trust funding is NOT required
• These schemes are NOT therapeutic area restricted
• A UK based collaborator is NOT a requirement
• Funding is NOT limited to academic institutions

• Looking for truly exceptional, paradigm shifting

projects that - due to the combination of potential high impact, risk, scale or complexity - warrant strategic status

• Wide range of biomedical developments can be

considered, including therapeutics, vaccines, diagnostics, enabling technologies, medical devices and regenerative medicine

Translation Fund

Translation Fund – Innovative Projects

• Aim to develop drug-like, small molecules that will be

the springboard for further research and development by the biotechnology and pharmaceutical industry in areas of unmet medical need

• Two entry points for projects
• “Early Stage” - ‘Screen to Lead’
• “Late Stage” – ‘Lead Optimisation to Clinic’

Seeding Drug Discovery

Seeding Drug Discovery - Success Stories

Core process The application process

Full Application Triage Committee Short Listing Preliminary Application Funding Committee Expert Reviews & Due Diligence

Top tips – what to consider

Risk Milestones IP Commercial Technical

Healthcare Impact

Regulatory Clinical

Business

Model, revenue generation, further funding requirements Informing clinical practice Awareness, preparation Feasibility, validation Current assets, potential new IP Timings, content, suitability Feasibility, team, market Competitive advantage,

• pportunity, reimbursement

Risk Milestones IP Commercial Technical

Funding model overview

Academia

• Revenue and Equity sharing

SME

• Unsecured Convertible loan
• Equity conversion 20% discount at an investment round

Pharma/Listed companies

• Milestone / Royalty based funding

Some awardees

• Dr Matthew Cooper at the University of Queensland
• Membrane-targeted antibiotics for complicated

skin and skin structure infections caused by multidrug-resistant bacteria.

• Dr Joseph Trapani at the Peter Mac Cancer Centre
• Perforin Inhibitors for the prevention of allogenic

bone marrow stem cell transplant rejection.

Seeding Drug Discovery in Australia

Technology Transfer Division The Wellcome Trust 215 Euston Road London NW1 2BE E a.mills-duggan@wellcome.ac.uk E techtransfer@wellcome.ac.uk W www.wellcome.ac.uk/techtransfer Email us to join our mailing list.

For further information